In silico DOCKING STUDIES OF BIOACTIVE COMPOUNDS IN CHLOROFORM EXTRACT OF Annona muricata LEAVES AGAINST HUMAN ANDROGEN RECEPTOR
DOI:
https://doi.org/10.46602/jcsn.v49i6.1026Abstract
It has become a major challenge for clinicians and research scientists to control or treat prostate inflammation due to drug resistance being commonly observed. Crude extracts from medicinal plants could serve as an alternative source for resistance-modifying agents because they contain numerous diverse secondary metabolites. It has been claimed that Anonna muricata possess anti-inflammatory, antioxidant, anticancer and antibacterial activities. However, little is still known about the bioactive compounds responsible for this activity. In this study, the plant`s bioactive compounds were extracted using chloroform and analyzed with Gas Chromatography-Mass Spectrometry (GC–MS). The drug likeness and ADME predictions were done with Swissadme webserver, while the molecular docking against human androgen receptor was done using Auto dock Vina. The docking results showed that the binding energy and interactions of 9,12-Octadecadienoic acid (Z,Z)- (-6.7kcal/mol); 1,2-Benzenedicarboxylic acid, butyl octyl ester (-6.1) and 8-Hexadecenal, 14-methyl-, (Z)- (6.1kcal/mol) ) were close to the control drug enzalutamide (-7.6 kcal/mol) and the protein native ligand methyltrienolone (-7.4kcal/mol). More so, these compounds showed drug likeness by obeying the limpiski rule qualifying them to be good drug candidate for control or treatment of prostate inflammations.Downloads
Published
2024-12-31
How to Cite
Ikpa, C. B. C. ., & Ikezu , U. J. M. (2024). In silico DOCKING STUDIES OF BIOACTIVE COMPOUNDS IN CHLOROFORM EXTRACT OF Annona muricata LEAVES AGAINST HUMAN ANDROGEN RECEPTOR . Journal of Chemical Society of Nigeria, 49(6). https://doi.org/10.46602/jcsn.v49i6.1026
Issue
Section
Articles
License
Copyright (c) 2024 C. B. C. Ikpa, U. J. M. Ikezu

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.